Business Context and Reporting Period
Company: Milestone Scientific Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: Milestone Scientific develops and markets proprietary dental and medical devices, primarily the STA Single Tooth Anesthesia System and CompuDent systems. The company relies on a network of distributors, including Henry Schein and Patterson Dental, for domestic sales and exclusive partners internationally.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Total Revenue | $2,204,819 | $1,402,153 |
| Gross Profit | $1,288,269 | $938,229 |
| Gross Margin | 58.4% | 67.0% |
| Net Loss | $(561,642) | $(615,885) |
| Loss Per Share (Basic/Diluted) | $(0.05) | $(0.05) |
| Cash and Cash Equivalents | $500,668 | $237,716 |
| Working Capital | $1,190,957 | N/A |
| Total Debt (Line of Credit + Notes) | $1,693,418 | N/A |
Note: Debt figures represent the carrying value net of discounts. The company has a $1.3 million line of credit and a $450,000 note payable, both from a stockholder.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 57.3% ($802,666) compared to Q1 2008. This was driven by a 59% increase in product sales, primarily due to the STA System. Domestic STA unit sales increased by $472,094, attributed to the termination of an exclusive distributor in Q2 2008 and the subsequent implementation of a non-exclusive distribution model.
- Gross Margin Compression: Gross margin decreased from 67% to 58.4%. Management attributes this to a reduction in the selling price of the STA System implemented in the second quarter of 2008.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased by 17.4% to $1.73 million. Increases were driven by higher marketing expenses ($286,439 increase), sales personnel costs, and third-party commissions. These were partially offset by a $92,419 decrease in professional accounting services following the completion of Sarbanes-Oxley initiatives.
- Net Loss Improvement: Net loss decreased by 8.8% ($54,243) year-over-year, despite higher operating expenses, due to the significant increase in gross profit dollars.
Guidance, Outlook, and Risks
- Going Concern Warning: The filing explicitly states that recurring losses and negative operating cash flows raise "substantial doubt about its ability to continue as a going concern." The company expects to meet obligations through December 31, 2009, but may need to raise additional capital.
- Management Changes: The Chief Executive Officer resigned on March 27, 2009. The Chairman of the Board has assumed the role of Interim CEO.
- Strategic Focus: Management plans to expand worldwide sales and marketing resources, with a specific emphasis on strengthening distribution channels in Europe. The company is also pursuing strategic collaborations for new medical applications of its CompuFlo technology.
- Debt Obligations: The $1.3 million line of credit must be repaid by June 30, 2010. The $450,000 note is due June 30, 2012. Both loans bear interest and include warrant components.
- Customer Concentration: Two customers accounted for approximately 70% of revenue in Q1 2009 (up from 93% in Q1 2008), indicating high reliance on key distributors.
Investor Verification Checklist
- Cash Runway: Verify if the company has secured additional financing to bridge the gap beyond December 31, 2009, given the "going concern" warning.
- Debt Repayment Plan: Assess the feasibility of repaying the $1.3 million line of credit due in June 2010, considering the company's current burn rate and lack of profitability.
- Revenue Sustainability: Confirm if the 59% revenue growth is sustainable or if it was a one-time benefit from the distribution strategy shift in 2008.
- Margin Trends: Monitor if the gross margin decline (from 67% to 58%) stabilizes or continues to compress due to pricing strategies.
- Executive Leadership: Track the appointment of a permanent CEO to replace the interim leadership.